Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NFE2L2 | Q16236 | 4/20 | 0.75 |
| ▸ | HCAR2 | Q8TDS4 | 2/20 | 0.75 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.52 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | TYR | P14679 | 1/20 | 0.43 |
| ▸ | CA7 | P43166 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.43 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | APP | P05067 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL820946 | 1.00 | NFE2L2 (0.75) | NFE2L2HCAR2KEAP1ALDH1A1ALOX15 | |
| SCHEMBL823097 | 1.00 | NFE2L2 (0.75) | NFE2L2HCAR2KEAP1ALDH1A1ALOX15 | |
| SCHEMBL821014 | 1.00 | NFE2L2 (0.75) | NFE2L2HCAR2KEAP1ALDH1A1ALOX15 | |
| Carbon Monoxide SCHEMBL11053883 | 0.91 | NFE2L2 (0.63) | NFE2L2HCAR2KEAP1ALDH1A1ALOX15 | |
| Methyl Sorbate SCHEMBL166359 | 0.89 | — | — | |
| Methyl Sorbate SCHEMBL821214 | 0.89 | — | — | |
| SCHEMBL11203918 | 0.89 | HCAR2 (0.71) | NFE2L2HCAR2KEAP1ALDH1A1ALOX15 | |
| Methyl Sorbate SCHEMBL14764128 | 0.89 | NFE2L2 (0.60) | NFE2L2HCAR2KEAP1ALDH1A1ALOX15 | |
| SCHEMBL13036666 | 0.89 | NFE2L2 (0.60) | NFE2L2HCAR2KEAP1ALDH1A1ALOX15 | |
| SCHEMBL11203915 | 0.89 | HCAR2 (0.71) | NFE2L2HCAR2KEAP1ALDH1A1ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3782976-B1 | SUSTAINABLE PROCESS FOR PRODUCING MUCONIC, HEXENEDIOIC AND ADIPIC ACID (AND THEIR ESTERS) FROM ALDARIC ACIDS BY HETEROGENEOUS CATALYSIS | KEMIJSKI INST (SI) | 2023-10-18 | — | — | EP | disclosed |
| CN-110023285-B | Process for producing epsilon-caprolactam | 东丽株式会社 | 2023-01-17 | — | — | CN | disclosed |
| EP-3782976-A1 | SUSTAINABLE PROCESS FOR PRODUCING MUCONIC, HEXENEDIOIC AND ADIPIC ACID (AND THEIR ESTERS) FROM ALDARIC ACIDS BY HETEROGENEOUS CATALYSIS | Kemijski Institut (SI) | 2021-02-24 | — | — | EP | disclosed |
| US-9666904-B2 | Secondary battery | NEC CORPORATION (JP) | 2017-05-30 | — | — | US | disclosed |
| US-20150194703-A1 | SECONDARY BATTERY | NEC CORPORATION (JP) | 2015-07-09 | — | — | US | disclosed |
| US-7727677-B2 | Nonaqueous electrolyte solution and lithium secondary battery using same | UBE INDUSTRIES, LTD. (JP) | 2010-06-01 | — | — | US | disclosed |
| EP-1758198-B1 | NON-AQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | UBE INDUSTRIES (JP) | 2009-07-08 | — | — | EP | disclosed |
| US-20080038644-A1 | Nonaques Electrolyte Solution And Lithium Secondary Battery Using Same | UBE INDUSTRIES, LTD. (JP) | 2008-02-14 | — | — | US | disclosed |
| EP-1758198-A1 | NONAQUEOUS ELECTROLYTE SOLUTION AND LITHIUM SECONDARY BATTERY USING SAME | Ube Industries, Ltd. (JP) | 2007-02-28 | — | — | EP | disclosed |
| US-6627580-B2 | Conjugated imines that are selectivite for tri-valent manganese ions; used for the treatment of manganese deficiency in plant cultivation | AKZO NOBEL N.V. (NL) | 2003-09-30 | — | — | US | disclosed |
| US-20020156308-A1 | Conjugated imines that are selectivite for tri-valent manganese ions; used for the treatment of manganese deficiency in plant cultivation | HAKANSON CHRISTER L (SE) | 2002-10-24 | — | — | US | disclosed |
| US-6458980-B1 | MANGANIC CHELATES OF THE CHELATING AGENTS AND SALTS WITH PERMANGANATE OR MANGANESE DIOXIDE CHELATING AGENTS (CHELANTS) OF THE GENERAL STRUCTURE: DEFICIENCY IN PLANT CULTIVATION. | AKZO NOBEL NV (NL) | 2002-10-01 | — | — | US | disclosed |
| EP-0998450-A1 | CHELATING AGENTS AND THEIR MANGANIC CHELATES | Akzo Nobel N.V. (NL) | 2000-05-10 | — | — | EP | disclosed |
| WO-1999002487-A1 | CHELATING AGENTS AND THEIR MANGANIC CHELATES | AKZO NOBEL N.V. (NL) | 1999-01-21 | — | — | WO | disclosed |
| US-4195184-A | Preparation of unsaturated monoesters by catalytic oxidative carbonylation of diolefins | ATLANTIC RICHFIELD COMPANY (US) | 1980-03-25 | — | — | US | disclosed |
| US-4189599-A | Preparation of dimethyl adipate by the hydrogenation of dimethyl hex-3-endioate | ATLANTIC RICHFIELD COMPANY (US) | 1980-02-19 | — | — | US | disclosed |
| US-4166913-A | COMPOUNDS OF PLATINUM GROUP AND OF COPPER OR IRON AS CATALYSTS | ATLANTIC RICHFIELD COMPANY (US) | 1979-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020156308-A1 | Conjugated imines that are selectivite for tri-valent manganese ions; used for the treatment of manganese deficiency in plant cultivation | MT-CO2, ZC3HAV1, MT-CO1 | NFE2L2 328/4885HCAR2 1015/4885KEAP1 469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.